Nathan Weinstein

Stock Analyst at Aegis Capital

(0.28)
# 4,387
Out of 5,182 analysts
59
Total ratings
13.79%
Success rate
-24.81%
Average return

Stocks Rated by Nathan Weinstein

Evogene
Sep 12, 2022
Maintains: Buy
Price Target: $100$80
Current: $0.81
Upside: +9,776.54%
DarioHealth
Aug 18, 2022
Maintains: Buy
Price Target: $400$300
Current: $7.46
Upside: +3,921.45%
VolitionRx
Aug 15, 2022
Maintains: Buy
Price Target: $9$6
Current: $0.16
Upside: +3,576.47%
Immunic
Aug 8, 2022
Maintains: Buy
Price Target: $40$35
Current: $0.96
Upside: +3,564.92%
Stereotaxis
Jul 12, 2022
Initiates: Buy
Price Target: $6
Current: $1.97
Upside: +204.57%
Oramed Pharmaceuticals
May 16, 2022
Maintains: Buy
Price Target: $35$30
Current: $3.83
Upside: +683.29%
Trevi Therapeutics
Mar 29, 2022
Initiates: Buy
Price Target: $10
Current: $15.40
Upside: -35.06%
MediWound
Mar 21, 2022
Maintains: Buy
Price Target: $63$49
Current: $17.35
Upside: +182.42%
Enveric Biosciences
Mar 8, 2022
Downgrades: Hold
Price Target: $63,000$1,800
Current: $3.65
Upside: +49,215.07%
Cingulate
Jan 11, 2022
Initiates: Buy
Price Target: $2,160
Current: $6.03
Upside: +35,720.90%
Initiates: Buy
Price Target: $120
Current: $1.69
Upside: +7,000.59%
Maintains: Buy
Price Target: $9$10
Current: $0.59
Upside: +1,604.16%
Maintains: Buy
Price Target: $60$56
Current: $40.07
Upside: +39.76%
Maintains: Buy
Price Target: $26$27
Current: $4.90
Upside: +451.02%
Maintains: Buy
Price Target: $40$35
Current: $1.07
Upside: +3,171.03%
Initiates: Buy
Price Target: $12
Current: $1.34
Upside: +795.52%
Initiates: Buy
Price Target: $75
Current: $24.52
Upside: +205.87%
Maintains: Buy
Price Target: $104$88
Current: $2.18
Upside: +3,936.70%
Initiates: Buy
Price Target: $180
Current: $0.61
Upside: +29,471.22%
Maintains: Buy
Price Target: $195$135
Current: $11.30
Upside: +1,095.22%
Initiates: Buy
Price Target: $14
Current: $8.01
Upside: +74.78%
Maintains: Buy
Price Target: $180$220
Current: $14.69
Upside: +1,398.13%
Initiates: Buy
Price Target: $8.5
Current: $3.00
Upside: +183.33%